Pacira Pharmaceuticals (PCRX) Gets a Buy Rating from Wedbush
Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $85. The company’s shares opened today at $43.30.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.4% and a 33.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $54.56 average price target, implying a 26.0% upside from current levels. In a report issued on June 11, Barclays also initiated coverage with a Buy rating on the stock with a $52 price target.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals’ market cap is currently $1.78B and has a P/E ratio of 246.54. The company has a Price to Book ratio of 5.44.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. Earlier this month, David Stack, the CEO & Chairman of PCRX bought 24,000 shares for a total of $73,560.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.